Neuroendocrine Carcinoma Market

The global neuroendocrine carcinoma market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increase in the number of cases of neuroendocrine tumors across the globe and rapid development in the tumor therapy.

Get Free Sample Report

Neuroendocrine carcinoma is a condition in which cancer develops in the neuroendocrine cells that secretes hormones into the body. This type of cancer causes tiredness and weight loss of patients. In this condition, the tumor grows painfully in neuroendocrine system of the body and have similar neuroendocrine cells. These similar cells are observed in organs such as kidneys, intestines, stomach, lungs that help control the speed of food through gastrointestinal tract and blood flow through the lungs. This tumor is a rare pernicious disorder that accounts for nearly one percent of all pernicious disorders. Some symptoms associated with neuroendocrine carcinoma are hypoglycemia, loss of appetite, headache, gastric ulcer, jaundice, diarrhea, unusual bleeding, fever persistent in specific area, and anxiety.

Around 12,000 people in the U.S. are diagnosed with neuroendocrine carcinoma each year, enlisted in the report by the American Society of Clinical Oncology. According to a report published by U.S. Surveillance Epidemiology and End Results Register, neuroendocrine carcinoma has expanded around 500%, compared prior to 2016. This is expected to provide growth opportunities for the market in the coming years.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing investment in research and development programs for the development of inexpensive next-generation sequencing tools and the ongoing clinical practices are expected to boost the market growth.
• Rising demand for curative method for pancreatic NETs and wide adoption of radiofrequency ablation are expected to drive the market growth.
• Governments’ policies for awareness initiatives and encouragement for the development of advanced treatment devices for neuroendocrine carcinoma is a key factor that can push the market growth.
• Major issues regarding severe consequences in the process of diagnosis such as bleeding, tumor spread, and pancreatic fistula are expected to hinder the adoption of the treatment. This is a key restraining factor of the market expansion.
• High cost of the diagnosis and prolonged treatment are some key factors expected to hamper the market growth during the forecast period.

Scope of the Report

The report on the global neuroendocrine carcinoma market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Gastrointestinal segment is expected to grow at a rapid pace

Based on sites, the global neuroendocrine carcinoma market is divided into lung, brain, pancreas, gastrointestinal, and others. The gastrointestinal segment is expected to grow at a rapid pace in the coming years as the majority of the cancer type is largely associated with gastric problems and several technology are available for the treatment. However, the lung segment is projected to hold a key market share during the forecast period owing to lungs affection due to tumor formation and rising cases of lungs tumor worldwide.

Get Free Sample Report

Surgery segment held a dominant market share

On the basis of therapy, the market is categorized as surgery, chemotherapy, and radiation therapy. The surgery segment is further bifurcated into radiofrequency ablation and local excision. The surgery segment held a dominant share of the market in 2020 and is expected to register a healthy growth rate in the coming years owing to wide adoption of radiofrequency ablation for the tumor treatment. Radiofrequency ablation is considered to be the only curative method for diagnosis as it offers high accuracy and effective in the treatment as compared to other conventional therapies. However, the chemotherapy therapy segment is anticipated to expand at a rapid pace during the forecast period owing to the initiatives taken by pharmaceutical companies and other authorities to develop the targeted therapy.

Imaging segment is projected to expand at a considerable CAGR

On the basis of diagnostic tools, the global neuroendocrine carcinoma market is segmented into biopsy, serology, imaging, and others. The serology segment is further classified as urine test, blood test, molecular test, and others, while the imaging segment includes CT scan, X-ray, PET scan, and others. The imaging segment is projected to expand at a considerable CAGR during the projected period due to increase in the acceptance of advance diagnostic imaging techniques that can detect clinically insignificant malignant tumors. Meanwhile, the serology segment is anticipated to expand at a rapid pace during the forecast period owing to the increase in number of tumor cases across the globe and rising adoption of CT scan for detecting the tumor.

North America is anticipated to constitute a key market share

In terms of regions, the global neuroendocrine carcinoma market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share in the coming years owing to new technology developments for the diagnosis neuroendocrine carcinoma and wide R&D investment from key players based in the region. Moreover, the presence of major global players in the region especially in the US present another key driver for the regional market growth. On the other hand, the market of Asia Pacific is anticipated to expand at a rapid pace during the forecast period due to the increase in the number of cases of NETs in the region. Furthermore, the wide prevalence of tumor cases among a large number of the people and increasing investment in the healthcare industry in the region play critical roles in the market expansion of Asia Pacific.

Get Free Sample Report

Segments

Segments Covered in the Report

The global neuroendocrine carcinoma market has been segmented on the basis of

Sites

• Lung
• Brain
• Pancreas
• Gastrointestinal
• Others

Therapy

• Surgery
  • Radiofrequency Ablation
  • Local Excision
• Chemotherapy
• Radiation Therapy

Diagnostic Tools

• Biopsy
• Serology
  • Urine Test
  • Blood Test
  • Molecular Test
  • Others
• Imaging
  • CT Scan
  • X-Ray
  • PET Scan
  • Others
• Others

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Novartis AG
• Amgen Inc.
• Boehringer Sohn AG & Ko. KG
• Dauntless Pharmaceuticals, Inc.
• Hutchison MediPharma Ltd.
• AVEO Pharmaceuticals Pvt. Ltd.
• Chiasma Inc.
• Aegis Therapeutics LLC
• Progenics Pharmaceuticals, Inc.
• Tarveda Therapeutics, Inc.
• Pfizer Inc.
• Jubilant Life Sciences Ltd.
• AbbVie Inc.
• Delcath Systems, Inc.
• Exelixis, Inc.; and others

Competitive Landscape

Key players competing in the global neuroendocrine carcinoma market are Novartis AG; Amgen Inc.; Boehringer Sohn AG & Ko. KG; Dauntless Pharmaceuticals, Inc.; Hutchison MediPharma Ltd.; AVEO Pharmaceuticals Pvt. Ltd.; Chiasma Inc.; Aegis Therapeutics LLC; Progenics Pharmaceuticals, Inc.; Tarveda Therapeutics, Inc.; Pfizer Inc.; Jubilant Life Sciences Ltd.; AbbVie Inc.; Delcath Systems, Inc.; and Exelixis, Inc.